Treatment of Hyperlipoproteinemias with Neomycin, Probucol and Tibric Acid

  • Tatu A. Miettinen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 82)

Abstract

Neomycin was introduced for the treatment of hypercholesterolemia more than 15 years ago (1) and has been used successfully for the long-term reduction of serum cholesterol without harmful side effects (2). Its use has been fairly limited, however, though it is effective even in severe forms of familial hypercholesterolemia with tendon xanthomata in which the normalization of serum cholesterol is usually unsuccessful with dietary and drug measures and is chieved only in a part of the patients even with the ileal by-pass operation (3).

Keywords

Placebo Cholesterol Diarrhea Dimethyl Triglyceride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. Samuel and A. Steiner, Proc. Soc. Exp. Biol. Med. 100, 193 (1959).PubMedGoogle Scholar
  2. 2.
    P. Samuel, C. M. Holtzman, and J. Goldstein, Circulation 35, 938 (1967).PubMedGoogle Scholar
  3. 3.
    H. Buchwald, R.B. Moore, and R.L. Varco, Circulation 49, Suppl. 1 (1974).Google Scholar
  4. 4.
    K.J. Breen, R.E. Bryant, J.D. Levinson, and S. Schenker, Ann. Int. Med. 76, 211 (1972).PubMedGoogle Scholar
  5. 5.
    D.P. Berk and T. Chalmers, Ann. Int. Med. 73, 393 (1970).PubMedGoogle Scholar
  6. 6.
    W.W. Faloon, Am. J. clin. Nutr. 23, 645 (1970).PubMedGoogle Scholar
  7. 7.
    G.A. Goldsmith, J.G. Hamilton, and O. N. Miller, Arch. Int. Med. 105, 512 (1960).CrossRefGoogle Scholar
  8. 8.
    R.C. Powell, W.T. Nunes, R.S. Harding, and J.B. Vacca, Am. J. clin. Nutrition 11, 156 (1962).Google Scholar
  9. 9.
    T.A. Miettinen, Exerpta Med., 1973 Int. Congr. Ser. No. 283,77.Google Scholar
  10. 10.
    A. Sedeghat, P. Samuel, J.R. Crouse, and E.H. Ahrens, Jr., J. clin. Invest. 55, 12 (1975).CrossRefGoogle Scholar
  11. 11.
    G.R. Thompson, J. Barrowman, L. Gutierrez, and R.H. Dowling, J. clin. Invest. 50, 319 (1971).PubMedCrossRefGoogle Scholar
  12. 12.
    T.A. Miettinen, in Proceedings of 6th Int. Congr. Pharmacol. 1974 in press.Google Scholar
  13. 13.
    P. Samuel, C.M. Holtzman, E. Meilman, and W. Perl, J. clin. Invest. 47, 1806 (1968).PubMedCrossRefGoogle Scholar
  14. 14.
    T.A. Miettinen, Eur. J. clin. Invest. 3, 256 (1973).Google Scholar
  15. 15.
    T.A. Miettinen, Postgrad. J. Med. 51, 71 (1975).Google Scholar
  16. 16.
    R.S. Harris, H. R. Gilmore, L.A. Bricker, I.M. Kiern, and E. Rubin, J.Am. Ger. Soc. 22, 167 (1974).Google Scholar
  17. 17.
    J.W. Barnhart, J.A. Sefranka, and D.D. Mcintosh, Am. J. clin. Nutr. 23, 1229 (1970).PubMedGoogle Scholar
  18. 18.
    T.A. Miettinen, Atherosder. 15, 163 (1972).CrossRefGoogle Scholar
  19. 19.
    T.A. Miettinen, Ann. Clin. Res. 2, 300 (1970).PubMedGoogle Scholar
  20. 20.
    A.A. Polachek, H.M. Katz, J. Sack, J. Selig, and M.L. Littman, Current Med. Res. Opinion 1, 323 (1973).CrossRefGoogle Scholar
  21. 21.
    H. Brown, and V.G. deWolfe, Clin. Pharmacol. Ther. 16, 44 (1974).PubMedGoogle Scholar
  22. 22.
    P. Bielmann, D. Brun, S. Moorjani, C. Gagné, P. Lupien, and Tétreault, Clin. Pharmacol. Ther. 17, 606 (1975).PubMedGoogle Scholar
  23. 23.
    L.A. Carlson, A.G. Olsson, L. Orö, S. Rössner, and G. Walldius, in Atherosclerosis III, Schettler, G. and Weizel, A.(eds.), Springer-Verlag, Berlin-Heidelberg-New York 1974, p.768.CrossRefGoogle Scholar
  24. 24.
    S.M. Grundy, E.H. Ahrens, Jr., G. Salen, P.H. Schreibman, and P.J. Nestel, J. Lipid Res. 13, 531 (1972).PubMedGoogle Scholar
  25. 25.
    D. Pertsemlidis, D. Panveliswalla, and E.H. Ahrens, Jr., Gastroenterology 66, 565 (1974).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Tatu A. Miettinen
    • 1
  1. 1.Second Department of MedicineUniversity of HelsinkiFinland

Personalised recommendations